Life Sciences Insight

Kaya 17 Gets CE Mark for Point-of-Care Coronavirus Antigen Test

Kaya 17 said last week that it has received the CE mark for its saliva-based SARS-CoV-2 antigen test.

According to the Livermore, California-based company, the point-of-care test detects viral antigens in saliva samples in 15 minutes and runs on a portable, briefcase-sized mobile reader instrument.

Kaya 17 said it intends to pursue Emergency Use Authorization from the US Food and Drug Administration for the test and that it is planning an initial public offering.